Bibliographic Details
| Title: |
Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial. |
| Authors: |
Jin JX, Ginde VR, Huhn S, Reichert P, Bertsch U, Fenk R, Besemer B, Boquoi A, Schroers R, von Metzler I, Hänel M, Mann C, Leypoldt LB, Heilmeier B, Scheid C, Peters-Regehr T, Blau IW, Müller-Tidow C, Luntz S, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Weinhold N, Hoffmann M, Benner A, Findeisen P, Weisel KC, Salwender HJ, Mai EK, Goldschmidt H |
| Corporate Authors: |
German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators |
| Source: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2026 Jul 10; Vol. 44 (20), pp. 1955. Date of Electronic Publication: 2026 Jun 08. |
| Publication Type: |
Journal Article; Published Erratum |
| Journal Info: |
Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE; In Process |
| Database: |
MEDLINE Ultimate |
